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Prevention of progression and remission/regression strategies
for chronic renal diseases: Can we do better now than five
years ago? The prevalence of chronic renal diseases is increas-
ing worldwide. There is a great need to identify therapies that
arrest disease progression to end-stage renal failure. Inhibi-
tion of renin-angiotensin system both by ACE inhibitors and
angiotensin II receptor antagonists is probably the best thera-
peutic option available. Several large, multicenter studies have
indeed shown a significant reduction in the risk of doubling
baseline serum creatinine or progression toward end-stage re-
nal failure in diabetic and nondiabetic patients with chronic
nephropathies treated with ACE inhibitors or angiotensin II re-
ceptor antagonists. However, the number of patients that reach
end-stage renal failure is still considerably high. Significant re-
duction of the incidence of end-stage renal disease is likely to be
achieved in the next future for chronic nephropathies, provided
that we can improve the degree of renoprotection. This goal may
be attainable with a more complex strategy than with a single or
dual pharmacologic intervention on the renin-angiotensin sys-
tem. Strict control of blood pressure and protein excretion rate,
lowering of blood lipids, tight glucose control for diabetics, and
lifestyle changes form part of the future multimodal protocol
for management of patients with chronic nephropathies.
In the world of nephrology, the 21st century coincided
with the reevaluation of its approach to chronic kidney
disease (CKD) management. Indeed, CKD is emerging
as a global threat to human health. Approximately 4.7%
of the United States population (8.3 million individuals)
has moderate to severely decreased kidney function, de-
fined as an estimated glomerular filtration rate (GFR)
<60 mL/min/1.73m2, and approximately 20 million have
kidney disease, as evidenced by proteinuria or GFR <90
mL/min/1.73m2. Moreover, there are now approximately
1.1 million people worldwide on renal replacement ther-
apy (RRT) and, according to reliable estimates, the num-
ber of patients on maintenance dialysis will double in 10
years [1]. The total cumulative cost for RRT in the next
decade will exceed US $1 trillion [2]. Thus, with the rising
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number of patients involved, costs will become extremely
high and prohibitive not only for developing countries.
Efforts have to be made to stop progression or even
induce remission/regression of renal disease to avoid end-
stage renal failure.
INSIGHTS FROM ANIMAL MODELS ON
MECHANISMS OF RENAL DISEASE
PROGRESSION AND THERAPEUTIC
INTERVENTIONS
In the past 2 decades, research in animals and peo-
ple has helped our understanding of the mechanisms of
how CKDs progress and has indicated possible preven-
tive tools [3, 4]. These studies have established that pro-
gressive deterioration of renal function is the result of
compensatory glomerular hemodynamic changes in re-
sponse to nephron loss due to the original insult that, in
turn, causes relentless injury of remaining intact nephrons
[4]. Enhancing intraglomerular capillary pressure impairs
the barrier’s size-selective function and causes excessive
protein ultrafiltration in animal models. In 1986, it was
suggested that proteins filtered through the glomeru-
lar capillary barrier might have intrinsic renal toxicity
and can play a contributory role in the progression of
renal damage [5]. Indeed, an excessive protein load of
podocytes can be a factor underlying progressive injury
of these glomerular cells that, by releasing transforming
growth factor b1 in the microenvironment, ultimately al-
low myofibroblast differentiation of mesangial cells [5].
Moreover, excessive protein reabsorption by proximal
tubuli provides further intrinsic toxicity to this nephron
segment. Thus, both in vitro and in vivo protein over-
load causes increased production of vasoactive and in-
flammatory mediators such as endothelin-1, monocyte
chemoattractant protein-1, normal T cell expressed and
secreted, and osteopontin [5]. The activation of a vari-
ety of molecules, including cytokines, growth factors, and
vasoactive substances, may result in abnormal accumula-
tion in the interstitium of extracellular matrix collagen,
fibronectin, and other components that are responsible
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for interstitial fibrosis. Proinflammatory mediators pro-
mote local recruitment of macrophages and lymphocytes
[5] that, in turn, can stimulate the transformation of in-
terstitial cells into myofibroblasts.
Modest derangement of these processes often escapes
clinical or laboratory detection because the myriad of
unimpaired nephrons compensate more or less com-
pletely. Beyond a certain level of injury, however, com-
pensatory adaptations no longer keep pace with nephron
loss. As a result, GFR declines and organic nitrogenous
wastes accumulate in plasma and other body fluids. In line
with these experimental observations is evidence that in
humans with nephropathy, more severe and persistent
proteinuria means more rapid progression of disease [4].
If interstitial inflammatory reaction and the con-
sequent fibrosis in chronic proteinuric nephropathies
were indeed a feature of protein overloading, limit-
ing protein traffic or the biologic effects of excessive
tubular reabsorption should prevent or retard renal dis-
ease progression. This is precisely what happens in ex-
perimental models of nondiabetic and diabetic chronic
nephropathies in which pharmacologic manipulation
with angiotensin-converting enzyme inhibitors (ACEI)
or angiotensin II receptor antagonists reduced protein-
uria and conferred protection [3–5]. Even regression of
structural renal injury can be achieved in these models
by renin-angiotensin system (RAS) blockade [6].
These observations suggested that chronic renal dis-
ease progresses by way of a common pathway of mech-
anisms and that therapeutic interventions inhibiting this
common pathway may be successful in slowing the rate
of progression of chronic renal disease, regardless of the
initiating cause. The concept of renoprotection has then
emerged.
RENOPROTECTION BY RAS BLOCKADE IN
PROTEINURIC NONDIABETIC
NEPHROPATHIES
Before 1995, several small, randomized trials of ACEI
in patients with nondiabetic renal disease were reported.
These studies, however, did not have uniform results. Pos-
sible sources of variability included different methods of
measuring renal function, different causes and severity
of renal disease, use of different ACEI, and small sample
sizes. Much more convincing evidence of a specific reno-
protective and dialysis-saving potential of ACEI therapy
was provided by the triad of Lancet publications gener-
ated by the Ramipril Efficacy in Nephropathy study from
1997 to 1999 [7–9]. The Ramipril Efficacy in Nephropathy
trial provided definitive evidence that an ACEI compared
with conventional antihypertensive therapy more effec-
tively slowed the rate of GFR at equivalent levels of blood
pressure control. Ramipril-treated patients also showed
a greater decrease in proteinuria (55% for ramipril vs. no
reduction for placebo), inversely related to the reduction
in GFR. This effect was seen across degrees of renal in-
sufficiency, and patients in the lowest tertile of GFR (10
to 30 mL/min) also benefited from treatment with ACEI
without a significant increase in the risk of hyperkalemia
[7].
RENOPROTECTION BY RAS BLOCKADE IN
DIABETIC NEPHROPATHY
RAS inhibition is effective in treating type 1 and type
2 diabetic nephropathy. ACEIs reduce the risk of pro-
gression of overt type 1 nephropathy to end-stage renal
disease (ESRD) and in type 1 patients with microal-
buminuria to overt nephropathy [10]. Evidence that
inhibition of the RAS was superior to conventional anti-
hypertensive therapy in patients with type 2 diabetes was
less clear until recently.
A recent trial evaluated the renoprotective effect of
the angiotensin-receptor blocker (ARB) irbesartan in hy-
pertensive patients with type 2 diabetes with incipient
nephropathy [11]. The end point of the study was the time
of onset of overt albuminuria. In 2 years’ follow-up, only
5.2% of patients receiving 300 mg of irbesartan reached
the end point, as compared with 14.9% of patients on
placebo. The groups had similar blood pressure control,
a finding that suggests that ARBs are renoprotective in-
dependent of their antihypertensive effect. The role of
ARBs in overt diabetic nephropathy was explored in 2
trials published in 2001. In one study, 1715 patients with
type 2 diabetic nephropathy were randomized to receive
ARB irbesartan [12], calcium-channel blocker amlodip-
ine, or placebo. The primary composite end point was
doubling of serum creatinine, ESRD, or death. Treatment
with irbesartan resulted in a risk reduction for a primary
composite end point of 20% lower than placebo and 23%
lower than amlodipine.
The Reduction of Endpoints in NIDDM with the An-
giotensin II Receptor Antagonist Losartan study evalu-
ated the renoprotective effect of losartan versus placebo
(on top of conventional antihypertensive therapy, with
the exclusion of ACEIs) in 1513 patients with overt
type 2 diabetic nephropathy [13]. The primary composite
end point was doubling of serum creatinine, ESRD, or
death. The ARB losartan reduced the incidence of dou-
bling serum creatinine of 25% and the risk of ESRD of
28%. Death rate was similar in the 2 groups, which both
attained the same blood pressure level. Proteinuria de-
clined by 35% in the losartan group. Data from the Re-
duction of Endpoints in NIDDM with the Angiotensin
II Receptor Antagonist Losartan study also indicate that
patients with severe renal insufficiency at baseline (serum
creatinine 2.1 to 3.6 mg/dL) did benefit more from pro-
tection against ESRD on losartan than those belonging
to better tertiles of baseline renal function. These findings
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indicate that there is no reason to stop treatment in pa-
tients with progressive chronic nephropathies, if the aim
is to retard ESRD and dialysis.
THE MULTIDRUG APPROACH AS ULTIMATE
TREATMENT FOR PROGRESSIVE RENAL
DISEASES
Evidence from clinical trials suggests that the current
practice can, at best, postpone ESRD for a few years
and will not allow most patients to avoid dialysis during
their lifetime. Nevertheless, significant reduction of the
incidence of ESRD is likely to be achieved in the near
future for chronic nephropathies, provided that we can
improve the degree of renoprotection. This goal may be
attainable with a more complex strategy than with a single
pharmacologic intervention on the RAS.
On the clinical ground, there are few trials that show
that the combination of an ACEI with an ARB af-
fords a greater renoprotection than each drug used
alone [14, 15]. The COOPERATE study [16] compared a
combined treatment of ACEI and ARB with monother-
apy of each drug at its maximum dose in patients with
nondiabetic renal disease. Eleven percent of patients on
combination treatment reached the combined primary
end point of time to doubling of serum creatinine con-
centration or ESRD compared with 23% of patients on
trandolapril alone (hazard ratio, 0.38; 95%CI 0.18–0.63;
P = 0.018) and 23% of those on losartan alone (hazard
ratio, 0.40; 95%CI 0.17–0.69; P = 0.016). In a prospec-
tive, randomized, crossover study of 24 patients with
nondiabetic, chronic nephropathies, we evaluated the ef-
fects on blood pressure, proteinuria, and renal hemo-
dynamics of an 8-week treatment with a combined half
dose of benazepril (10 mg/d) and valsartan (80 mg/d) as
compared with those achieved by a full recommended
dose of benazepril (20 mg/d) or valsartan (160 mg/d)
alone [17]. Despite comparable changes in blood pres-
sure and GFR, combined therapy decreased proteinuria
more than benazepril (−56% vs. −45.9%, P = 0.02) and
valsartan (−41.5%, P = 0.002) alone. However, a signif-
icant number of patients treated with ACEI/ARB did
show only partial antiproteinuric response, and this her-
alds a progressive loss of renal function in most cases. In-
tensive, multimodal approach to the treatment of chronic
nephropathies, which includes blood pressure control, in-
hibition of the RAS, glucose control, and lipid control,
should be more effective than standard approaches.
The multidrug approach to chronic nephropathies has
been formalized in an interventional protocol that has
been named remission clinic [18]. Patients with CKD and
proteinuria greater than 1 g/24 h are initially treated with
a low starting dose of an ACEI, which is then increased up
to the maximum dose. Then, if the goals of blood pres-
sure <120/80 mm Hg and proteinuria <0.3 g/24 h are
not achieved, an ARB is added at half-maximum dose.
Again, the dose is increased stepwise. Throughout this
up-titration of ACEI or ARB, the addition of diuretics is
usually needed for optimal blood pressure control or pre-
vention of hyperkalemia. If, after this step, target blood
pressure and proteinuria are still not achieved, the next
antiproteinuric drug to be added is usually a nondihy-
dropiridinic calcium-channel blocker. In those with low-
density lipoprotein cholesterol >100 mg/dL, a statin is
added, and in those with diabetes, glycemic control is re-
inforced to achieve hemoglobin A1c <7.5%. Both inter-
ventions (lipid reduction and tight glycemic control) are
supposed to contribute to renoprotection.
In searching for a more effective treatment, the role
of lifestyle changes should not be overlooked. Smoking
cessation per se may reduce disease progression by 30%,
which qualifies as the single most important renoprotec-
tive measure [19]. Physical activity has always been con-
sidered instrumental in the loss of excess weight, but it
may have an intrinsic favorable effect. The efficacy of
the multifactorial intervention is supported by a target-
driven, long-term (mean follow-up 7.8 years), intensified
intervention aimed at multiple risk factors in 80 patients
with type 2 diabetes and microalbuminuria, which re-
duced the risk of nephropathy and cardiovascular and
microvascular events by about 50% [20].
CAN WE ACHIEVE REMISSION/REGRESSION
WITH MULTIFACTORIAL INTERVENTION?
Regression of renal lesions could have a significant im-
pact on progressive renal disease and its sequelae. Evi-
dence that regression of CKD and the underlying lesion is
achievable in humans can only be indirect, but it is fairly
consistent and encouraging. Clinical findings of reduction
of proteinuria to <0.3 g/24 h and increasing GFR indi-
cate regression of proteinuric chronic nephropathy, pos-
sibly reflecting improvement of renal structural changes
[18]. Combined therapy with ACEI, ARB, diuretics, and
statins blunted proteinuria and stabilized GFR for almost
10 years in a young girl with nephrotic-range protein-
uria who might otherwise have required dialysis within
months [21]. In a series of ours, 26 patients whose pro-
teinuria had been at least 3 g for more than 6 months,
despite ACEI therapy, were given a standardized mul-
tidrug treatment including diuretics, ACEI, ARB, statins,
and nondihidropyridine calcium-channel blockers. Nine-
teen (73%) of these patients achieved full remission of
proteinuria and their renal function stabilized over 24
months. Whether in parallel with clinical remission re-
nal damage can also be reduced is still matter of investi-
gation. Repeated biopsy for a trend of renal damage to
regress, leading to less mesangial expansion, more open
capillaries, and less interstitial fibrosis supports the evi-
dence [22]. At least 10 years were needed to reverse the
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lesions, which is entirely consistent with the concept that
the timing of institution of therapy, besides drug doses
and combinations, is critical in the human setting exactly
as it is in the experimental animal [23].
CONCLUSION
The current therapeutic approach for proteinuric
chronic nephropathies is based on blockade of the RAS
with ACEI and/or ARBs that limit proteinuria and re-
duce GFR decline and risk of ESRD more effectively
than other antihypertensive treatments. Full remission
of the disease, however, is seldom obtained, particu-
larly when pharmacologic intervention is started late. For
those who do not respond, treatment procedure to remis-
sion and/or regression must include a multimodal strategy
to implement renoprotection. Preventing nephropathy is,
however, more important than retarding progression, and
this should be the next step for nephrologists [24].
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